Department of Neurology, University of Utah, Salt Lake City, Utah, United States.
Department of Neurology, University of Utah, Salt Lake City, Utah, United States.
J Stroke Cerebrovasc Dis. 2021 Nov;30(11):106065. doi: 10.1016/j.jstrokecerebrovasdis.2021.106065. Epub 2021 Aug 26.
Hyperglycemia is common after acute ischemic stroke and is associated with worse outcome, but intensive glucose control has not improved outcome. There is also a racial disparity in outcome after stroke, with Black patients more likely to have functional impairment than whites. We aimed to evaluate if there were racial differences in outcomes in acute ischemic stroke patients treated with intensive glucose control.
We performed a post-hoc analysis of the Stroke Hyperglycemia Insulin Network Effort (SHINE) trial to determine if Black patients had worse functional outcome than whites and if standard versus intensive glucose control modified that association. We included non-Hispanic white and Black patients. The primary outcome was excellent functional outcome (90-day modified Rankin Score of 0-1). To account for patient clustering by study site, we fit mixed-effects logistic regression models to our outcome and tested the interaction of treatment and race.
We included 895 patients, of which 304 (34%) were Black and 591 (66%) were white. The rate of excellent outcome was 31.6% in Black patients versus 41.0% in white patients (p=0.006). After adjusting for potential confounders, the odds ratio for excellent outcome in Black patients was 0.54 (95% CI 0.38-0.77). The interaction term between treatment and race was significant (p=0.067). In the intensive treatment arm, Black patients had a predicted probability of excellent outcome of 26.4% (20.1-32.8) versus 42.7% (37.6-47.9) for white patients (p<0.001), while in the standard treatment arm the difference was not significant.
Black patients with acute ischemic stroke and hyperglycemia had worse functional outcome at 90 days than white patients, particularly if given intensive glucose control. These findings are from a post-hoc analysis and may be confounded, thus warrant additional study.
急性缺血性脑卒中后常发生高血糖,且与预后不良相关,但强化血糖控制并未改善预后。脑卒中后也存在种族差异,黑人患者的功能障碍比白人更常见。我们旨在评估强化血糖控制治疗的急性缺血性脑卒中患者的结局是否存在种族差异。
我们对卒中高血糖胰岛素网络效应(SHINE)试验进行了事后分析,以确定黑人患者的功能结局是否比白人患者更差,以及标准血糖控制与强化血糖控制是否改变了这种关联。我们纳入了非西班牙裔白人和黑人患者。主要结局为良好的功能结局(90 天改良Rankin 评分 0-1)。为了考虑到患者按研究地点聚类,我们使用混合效应逻辑回归模型拟合我们的结局,并检验了治疗与种族的交互作用。
我们纳入了 895 名患者,其中 304 名(34%)为黑人,591 名(66%)为白人。黑人患者的良好结局发生率为 31.6%,白人患者为 41.0%(p=0.006)。在调整了潜在混杂因素后,黑人患者良好结局的优势比为 0.54(95%CI 0.38-0.77)。治疗与种族之间的交互作用项具有统计学意义(p=0.067)。在强化治疗组中,黑人患者的良好结局预测概率为 26.4%(20.1-32.8),而白人患者为 42.7%(37.6-47.9)(p<0.001),而在标准治疗组中差异无统计学意义。
急性缺血性脑卒中合并高血糖的黑人患者 90 天的功能结局比白人患者差,尤其是给予强化血糖控制时。这些发现来自于事后分析,可能存在混杂因素,因此需要进一步研究。